Welcome to our dedicated page for Keros Therapeutics news (Ticker: KROS), a resource for investors and traders seeking the latest updates and insights on Keros Therapeutics stock.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders. The company’s mission focuses on addressing high unmet medical needs through innovative therapeutic solutions.
At the forefront of Keros’ pipeline is KER-050, a protein therapeutic product candidate aimed at treating low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes (MDS) and myelofibrosis. KER-050 is currently in Phase 2 clinical trials, with promising data presented at the 65th American Society of Hematology meeting showcasing its potential to ameliorate ineffective hematopoiesis and improve patient outcomes.
Another key product in development is KER-012, a small molecule being developed for the treatment of pulmonary arterial hypertension (PAH) and cardiovascular disorders. This candidate is also in Phase 2 trials and has shown encouraging preliminary results, particularly in treating bone loss disorders such as osteoporosis and osteogenesis imperfecta.
KER-047, another small molecule candidate, targets anemia and the rare genetic disorder, fibrodysplasia ossificans progressiva (FOP). Currently in Phase 1 clinical trials, KER-047 aims to address significant gaps in treatment for these conditions.
Financially, Keros reported a net loss of $39.4 million for the third quarter of 2023, attributed to increased research and development efforts. Despite this, the company maintains a solid cash balance of $287.9 million as of September 30, 2023, expected to fund operations into the fourth quarter of 2025. The recent public offering of $120 million in common stock further strengthens their financial position.
Keros’ strategic partnerships and collaborations play a crucial role in its development strategy. The company’s agreement with Hansoh (Shanghai) Healthtech Co., Ltd. in 2021 for manufacturing technology transfer is a significant step towards commercial scalability.
The company’s commitment to advancing its pipeline and achieving clinical milestones is evident through its continuous updates and transparent communication with stakeholders. Upcoming milestones include updates on the KER-050 and KER-012 programs, reflecting Keros’ proactive approach in driving innovation and improving patient lives.
Keros Therapeutics remains a leader in leveraging the transforming growth factor-beta (TGF-β) family of proteins, aiming to provide meaningful and potentially disease-modifying benefits to patients.
Keros Therapeutics (NASDAQ: KROS) has announced the voluntary halt of dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms of its Phase 2 TROPOS trial, which studies cibotercept (KER-012) for pulmonary arterial hypertension (PAH). This decision follows the unanticipated observation of pericardial effusion adverse events.
The 1.5 mg/kg treatment arm continues following a risk-benefit assessment by the independent Data Monitoring Committee and Keros team. The trial is fully enrolled, and the company maintains its timeline to present topline data from all treatment arms in Q2 2025. The FDA and other regulatory authorities have been notified of these developments.
Keros Therapeutics (KROS) presented data from two ongoing Phase 2 clinical trials of elritercept at the 66th ASH Annual Meeting. The first trial in lower-risk myelodysplastic syndromes (MDS) showed that 55.2% of patients achieved overall erythroid response, with a median transfusion independence duration of 134.1 weeks. Of high transfusion burden patients, 31.4% achieved transfusion independence for at least eight weeks.
The second trial in myelofibrosis (MF) demonstrated that 82.8% of non-transfusion dependent patients showed increased hemoglobin levels, while 63.4% of transfusion-dependent patients showed reduced transfusion burden. Additionally, 40% of patients showed reduced spleen volume, and 66.7% experienced reduced disease symptoms at week 24.
Elritercept was generally well-tolerated in both trials, with most adverse events being mild to moderate.
Keros Therapeutics (NASDAQ: KROS) has entered into an exclusive global license agreement with Takeda for elritercept, a drug currently in Phase 2 clinical trials for myelodysplastic syndrome (MDS) and myelofibrosis (MF). Under the agreement, Takeda will obtain exclusive rights to develop, manufacture, and commercialize elritercept worldwide, except for mainland China, Hong Kong, and Macau. Keros will receive a $200 million upfront payment and is eligible for additional milestone payments potentially exceeding $1.1 billion, plus tiered royalties on net sales. The deal is expected to extend Keros' operational runway into Q4 2028.
Takeda has entered into an exclusive licensing agreement with Keros Therapeutics for elritercept, a late-stage activin inhibitor designed to treat anemia in hematologic cancers. The agreement grants Takeda exclusive global rights outside mainland China, Hong Kong, and Macau. Elritercept targets myelodysplastic syndromes (MDS) and myelofibrosis (MF), and has received FDA Fast Track designation for MDS treatment. The drug has shown promising clinical activity in early studies. Takeda will pay $200 million upfront, plus potential milestone payments and royalties. Two Phase 2 trials are ongoing, with a Phase 3 RENEW trial for MDS patients starting soon.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in two upcoming healthcare conferences. The company's CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 10:30 a.m. ET, and the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 3:00 p.m. ET. Both presentations will be in a fireside chat format, with archived replays available on the Keros website for 90 days after each event.
Keros Therapeutics (NASDAQ: KROS) reported its Q3 2024 financial results and business highlights. The company announced completion of enrollment ahead of schedule in Phase 2 TROPOS trial of cibotercept. Financial results showed a net loss of $53.0 million compared to $39.4 million in Q3 2023. R&D expenses increased to $49.2 million from $34.1 million year-over-year. The company's cash position strengthened to $530.7 million, expected to fund operations into Q3 2027. Keros also appointed Yung H. Chyung as Chief Medical Officer effective November 1, 2024.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß signaling disorders, has announced its upcoming participation in the Guggenheim Healthcare Innovation Conference. Chair and CEO Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on November 13, 2024, at 3:30 p.m. Eastern time.
The presentation will be accessible via live audio webcast, with an archived version available on the company's investor relations website for 90 days after the event.
Keros Therapeutics (Nasdaq: KROS) has announced the presentation of three abstracts from its hematology program at the 66th American Society of Hematology (ASH) Annual Meeting from December 7-10, 2024. The presentations will showcase additional results from two ongoing Phase 2 clinical trials of elritercept (KER-050).
The trials focus on patients with lower-risk myelodysplastic syndrome (MDS) and myelofibrosis (MF). The presentations will highlight improvements in hematological parameters, quality of life, and clinical benefits of elritercept both as monotherapy and in combination with ruxolitinib. The abstracts were made public on the ASH website on November 5, 2024.
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company, has announced an updated time for its presentation at the 2024 Cantor Global Healthcare Conference. The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation on Thursday, September 19, 2024, at 8:00 a.m. Eastern time.
Keros focuses on developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The presentation will be available via live audio webcast, with an archived replay accessible on the company's investor relations website for up to 90 days after the event.
Keros Therapeutics (Nasdaq: KROS) has announced the closure of screening for its TROPOS trial, a Phase 2 clinical study of cibotercept (KER-012) in combination with background therapy for patients with pulmonary arterial hypertension (PAH). The company expects to complete enrollment by the end of September and present topline data in Q2 2025, earlier than initially anticipated due to high demand and rapid enrollment. Keros, focused on developing therapies for disorders linked to dysfunctional TGF-ß family protein signaling, aims to bring a potentially differentiated treatment option to PAH patients. The company's leadership expressed gratitude to the investigators, research staff, and patients involved in this significant clinical research milestone.
FAQ
What is the current stock price of Keros Therapeutics (KROS)?
What is the market cap of Keros Therapeutics (KROS)?
What is Keros Therapeutics’ main focus?
What are the key products in Keros Therapeutics’ pipeline?
What recent achievements has Keros Therapeutics reported?
What is the financial condition of Keros Therapeutics?
How is Keros Therapeutics advancing its clinical trials?
What partnerships does Keros Therapeutics have?
What disorders does KER-050 target?
What is the significance of Fast Track designation for KER-050?
When can we expect updates on KER-012?
What role does the TGF-β family of proteins play in Keros Therapeutics’ research?
